SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces The Commencement Of An Investigation Involving Possible Securities Fraud Violations By Certain Officers And Directors Of Arrowhead Pharmaceuticals, Inc. -- ARWR

Levi & Korsinsky announces it has commenced an investigation of Arrowhead Pharmaceuticals, Inc. ("Arrowhead Pharmaceuticals" or the "Company") (NASDAQ:ARWR) concerning possible violations of federal securities laws by certain officers and directors.

On November 8, 2016, after the close of the market, Arrowhead Pharmaceuticals announced that the United States Food & Drug Administration had decided to place a clinical hold on the Company's Heparc-2004 clinical study of ARC-520. According to the company, the hold stems from deaths at the highest dose of an ongoing non-human primate toxicology study; these deaths are currently under investigation. Following this news, shares of Arrowhead Pharmaceuticals shares fell from a close of $6.11 per share to a close of $4.45 per share on November 9, 2016. To obtain additional information about the investigation, go to:

http://zlk.9nl.com/arrowhead-pharmaceuticals

or contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972.

Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut and Washington D.C. The firm's attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:Levi & Korsinsky, LLPJoseph E. Levi, Esq.30 Broad Street - 24th FloorNew York, NY 10004Tel: (212) 363-7500Toll Free: (877) 363-5972Fax: (212) 363-7171 www.zlk.com

View source version on businesswire.com: http://www.businesswire.com/news/home/20161109005901/en/
Copyright Business Wire 2010

If you liked this article you might like

Take a Look at These Stocks Poised to Trade Higher

These 5 Stocks Under $10 Could Explode Higher

Premarket Biotech Movers: Synergy, Arrowhead, BioCryst

These 3 Biotech Stocks Are Already Moving Wildly on Thursday

The Worst Biopharma CEOs of 2016 Are ...